Braavos leads SpyBiotech's $32.5m series-A

Another new investor, Oxford Investment Consultants, also joined the round, alongside participation from founding investors Oxford Sciences Innovation and GV, as well as the UK Government's Future Fund, converting a prior convertible loan into equity.

The company has appointed Lutz Giebel as chairman. He has served on the boards of 16 biotechnology and pharmaceutical companies and held several executive positions, including managing partner at SV Life Sciences, based in San Francisco. SpyBiotech has also appointed Andre Crawford-Brunt, general partner of Braavos Investment Advisers to its board.

Proceeds will advance the clinical development of SpyBiotech's novel vaccine technology platform.

Previous funding
Oxford Sciences Innovation and GV, Google's investment arm, provided the company with £4m in March 2017.

Company
The company produces a drug that has broad applicability across a number of infectious diseases, and in a range of other areas, such as oncology, which it also plans to explore in clinical development, according to a statement. SpyBiotech span out of the University of Oxford in 2017.

People
Braavos Investment Advisers – Andre Crawford-Brunt (general partner).
Oxford Sciences Innovation – James Wong (principal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• healthcare